7月10日，Tempus AI盘中下跌5.01%，报58.37美元/股，成交额5910.46万美元。
消息面上，此前Biovica International AB宣布终止与Tempus AI的合作协议，并明确表示双方合作未能促成产品商业化上市或产生任何收入。与此同时，公司CEO Eric P. Lefkofsky通过10b5-1计划减持约126,250股，成交价区间54.82至59.59美元，且公司近日再度提交拟议出售证券文件，高管持续减持叠加合作失败消息仍在压制市场情绪。此外，Freedom Capital Markets近期对公司启动覆盖给予持有评级，目标价59美元，当前股价已跌破该目标位，进一步加剧投资者观望态度。
Tempus AI通过人工智能在医疗保健领域的实际应用，致力于释放精准医疗的力量，将实验室结果与患者临床数据连接，使诊断测试更加智能化和个性化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.